Antifungal agents of use in animal health - Chemical, biochemical and pharmacological aspects

Journal of Veterinary Pharmacology and Therapeutics

Volumn 26, Issue 1, 2003, Pages 5-29

  Vanden Bossche, Hugo ^a   Engelen, M ^b   Rochette, F ^b  

^a Janssen Animal Health BVBA ^*  (Belgium)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLAMINE DERIVATIVE; AMPHOTERICIN B DEOXYCHOLATE; ANTHELMINTIC AGENT; ANTIFUNGAL AGENT; BENZIMIDAZOLE DERIVATIVE; CICLOPIROXOLAMINE; CLOTRIMAZOLE; COLCHICINE; ECONAZOLE; ENILCONAZOLE; FLUCONAZOLE; FLUCYTOSINE; GRISEOFULVIN; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NAFTIFINE; NATAMYCIN; NYSTATIN; PARCONAZOLE; POLYENE; PYRIMIDINE; PYRROLE DERIVATIVE; SERTACONAZOLE; TERBINAFINE; THIOCARBAMIC ACID DERIVATIVE; TIABENDAZOLE; TOLNAFTATE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL HEALTH; ANIMAL USE; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; BLOOD TOXICITY; BONE MARROW DEPRESSION; BURNING SENSATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG UPTAKE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LIVER TOXICITY; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW; SKIN DISEASE; SKIN IRRITATION; TASTE DISORDER; TERATOGENESIS; THROMBOCYTOPENIA; TINEA; VETERINARY MEDICINE;

ANIMALS; ANTIFUNGAL AGENTS; CLOTRIMAZOLE; DRUG RESISTANCE, FUNGAL; ECONAZOLE; FLUCONAZOLE; FLUCYTOSINE; GRISEOFULVIN; IMIDAZOLES; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NAPHTHALENES; NATAMYCIN; NYSTATIN; THIABENDAZOLE; TOLNAFTATE; VETERINARY DRUGS;

ANIMALIA; TINEA;

EID: 0037292953     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2885.2003.00456.x     Document Type: Review

References (280)

1. Albertson, G.D., Niimi, M., Cannon, R.D. & Jenkinson, H.F. (1996) Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrobial Agents and Chemotherapy, 40, 2300-2305.
2. Andreoli, T.E. (1974) The structure and function of amphotericin B-cholesterol pores in lipid bilayer membranes. Annals of the New York Academy of Sciences. 235, 448-468.
3. Aparicio, J.F., Colina, A.J., Ceballos, E. & Martin, J.F. (1999) The biosynthetic gene cluster for the 26-membered ring polyene macrolide pimaricin. A new polyketide synthase organisation encoded by two subclusters separated by functionalization genes. Journal of Biological Chemistry, 274, 10133-10139.
4. Aparicio, J.F., Fouces, R., Mendes, M.V., Olivera, N. & Martin, J.F. (2000) A complex multienzyme system encoded by five poliketide synthase genes is involved in the biosynthesis of the 26-membered polyene macrolide pimaricin in Streptomyces natalensis. Chemistry and Biology, 7, 895-905.
5. Arias, A., Arevalo, M.P., Andreu, A., Rodriguez, C. & Sierra, A. (1996) Candida glabrata: in vitro susceptibility of 84 isolates to eight antifungal agents. Chemotherapy, 42, 107-111.
6. Armstrong, D. & Schmitt, H.J. (1990) Older drugs. In Chemotherapy of Fungal Diseases. Ed. Ryley, J.F. pp. 439-454. Springer Verlag, Berlin.
7. Arthington-Skaggs, B.A., Motley, M., Warnock, D.W. & Morrison, C.J. (2000) Comparative evaluation of PASCO and national committee for clinical laboratory standards M27A broth microdilution methods for antifungal drug susceptibility testing of yeasts. Journal of Clinical Microbiology, 38, 2254-2260.
8. Artis, W.M., Odle, B.M. & Jones, H.E. (1981) Griseofulvin resistant dermatophytosis correlates with in vitro resistance. Archives of Dermatology, 117, 16-19.
9. Asai, K., Tsuchimori, N. Okonogi, K., Perfect, J.R., Gotoh, O. & Yoshida, Y. (1999) Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450. Antimicrobial Agents and Chemotherapy, 43, 1163-1169.
10. Barchiesi, F., Calabrese, D., Sanglard, D., Falconi di Francesco, L., Caselli, F., Giannini, D., Giacometti, S., Gavaudan, S. & Scalise, G. (2000) Experimental induction of fluconazole resistance in Candida tropicdis ATCC750. Antimicrobid Agents and Chemotherapy, 44, 1578-1584.
11. Barchiesi, F., Colombo, A.L., McGough, D.A., Fothergill, A.W. & Rinaldi, M.G. (1994) In vitro activity of itraconazole against fluconazole-susceptible and - resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus. Antimicrobial Agents and Chemotherapy, 38, 1530-1533.
12. Barrett-Bee, K.J., Lane, A.C. & Turner, R.W. (1986) The mode of action of tolnaftate. Journal of Medical and Veterinary Mycology, 24, 155-160.
13. Barry, A.L., Pfaller, M.A., Brown, S.D., Espinel-Ingroff, A., Ghannoum, M.A., Knapp, C., Rennie, R.P., Rex, J.H. & Rinaldi, M.G. (2000) Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. Journal of Clinical Microbiology, 38, 3457-3459.
14. Bartlett, M.S., Edlind, T.D., Durkin, M.M., Shaw, M.M., Queener, S.F. & Smith, J.W. (1992) Antimicrotubule benzimidazoles inhibit in vitro growth of Pneumocystis carinii. Antimicrobial Agents and Chemotherapy, 36, 779-782.
15. Barug, D., Samson, R.A. & Kerkenaar, A. (1983) Microscopic studies of Candida albicans and Torulopsis glabrata after in vitro treatment with bifonazole. Arzneimittel-Forschung, 33, 528-537.
16. Bennett, J.E. (1992) Developing drugs for the deep mycoses: a short history. In New Strategies in Fungal Disease. Eds Bennett, J.E., Hay, R.J. & Peterson, P.K. pp. 3-12. Churchill Livingstone, Edinburgh.
17. Boelaert, J., Daneels, R., Van Landuyt, H. & Symoens, J. (1976) Miconazole plasma levels in healthy subjects and patients with impaired renal function. Chemotherapy, 6, 165-169.
18. Bohets, H., Lavrijsen, K., Hendrickx, J., van Houdt, J., van Genechten, V., Verboven, P., Meuldermans, W. & Heykants, J. (2000) Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. British Journal of Pharmacology, 129, 1655-1667.
19. Bolard, J. (1986) How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochimica Biophysica Acta, 864, 257-304.
20. Borgers, M., Vanden Bossche, H. & Cauwenbergh, G. (1986) The pharmacology of agents used in the treatment of pulmonary mycoses. Clinics in Chest Medicine, 7, 439-452.
21. Bouchara, J.P., Zouhair, R., Le Boudouil, S., Renier, G., Filmon, R., Chabasse, D., Hailer, J.B. & Defontaine, A. (2000) In-vivo selection of an azole-resistant petite mutant of Candida glabrata. Journal of Medical Microbiology, 49, 977-984.
22. Brajtburg, J., Gruda, I. & Kobayashi, G.S. (1992) Amphotericin B: studies focused on improving its therapeutic efficacy. In Recent Progress in Antifungal Chemotherapy. Eds Yamaguchi, H., Kobayashi, G.S. & Takahashi, H. pp. 65-75. Marcel Dekker. Inc., New York.
23. Brajtburg, J., Powderly, W.G., Kobayashi, G.S. & Medoff, G. (1990) Amphotericin B: current understanding of mechanisms of action. Antimicrobial Agents and Chemotherapy, 34, 183-188.
24. Brammer, K.W. & Tarbit, M.H. (1987) A review of the pharmacokinetics of fluconazole (UK-49,858) in laboratory animals and man. In Recent Trends in the Discovery and Evaluation of Antifungal Agents. Ed. Frontling, R.A. pp. 141-149. J.R. Prous Science Publishers S.A., Barcelona.
25. +-ATPase in Fusarium oxysporum. Journal of General Microbiology, 138, 1579-1586.
26. Brasseur, R., Vandenbosch, C., Vanden Bossche, H. & Ruysschaert, J.M. (1983) Mode of insertion of miconazole, ketoconazole and deacylated ketoconazole in lipid layers. Biochemical Pharmacology, 32, 2175-2180.
27. Brautaset, T., Sekurova, O.N., Sletta, H., Ellingsen, T.E., StrLm, A.M., Valla, S. & Zotchev, S.B. (2000) Biosynthesis of the polyene antifungal antibiotic nystatin in Streptomyces noursei ATCC 11455: analysis of the gene cluster and deduction of the biosynthetic pathway. Chemistry and Biology, 7, 395-403.
28. Bräutigam, M. & Weidinger, G. (1993) Clinical experience with naftifine. In Cutaneous Antifungal Agents. Eds Rippon, J.W. & Fromtling, R.A. pp. 99-115. Marcel Dekker, Inc., New York.
29. Büchel, K.W., Draber, W., Regel, E. & Plempel, E. (1972) Synthesen und Eigenschaften von Clotrimazol und weiteren Antimykotischen 1-Triphenylmethylimidazolen. Arzneimittel-Forschung, 22, 1260-1272.
30. Burghoorn, H.P., Soteropoulos, P., Paderu, P., Kashiwazaki, R. & Perlin, D.S. (2002) Molecular evaluation of the plasma membrane proton pump from Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 46, 615-624.
31. Burland, T.G. & Gull, K. (1984) Molecular and cellular aspects of the interaction of benzimidazole fungicides with tubulin and microtubules. In Mode of Action of Antifungal Agents. Eds Trinci, A.PJ. & Ryley, J.F. pp. 299-320. Cambridge University Press, Cambridge.
32. Burt, E.T. (2001) Current approaches to the treatment of Candida albicans infections. Expert Opinion on Therapeutic Patents. 11, 269-282.
33. 14C-griseofulvin metabolism in rat liver microsomes, isolated perfused rat livers, and in rats with bile duct cannulas. Drug Metabolism and Disposition, 3, 487-493.
34. Chapman, S.W., Rogers, P.D., Rinaldi, M.G. & Sullivan, D.C. (1998) Susceptibilities of clinical and laboratory isolates of Blastomyces dermatitidis to ketoconazole, itraconazole, and fluconazole. Antimicrobial Agents and Chemotherapy, 42, 978-980.
35. Chaudhuri, A.R. & Luduena, R.F. (1996) Griseofulvin: a novel interaction with bovine brain tubulin. Biochemical Pharmacology, 51, 903-909.
36. Chiew, Y.Y., Sullivan, P.A. & Shepherd, M.G. (1982) The effect of ergosterol and alcohols on germ-tube formation and chitin synthase in Candida albicans, Canadian Journal of Biochemistry, 60, 15-20.
37. Cornelissen, F. & Vanden Bossche, H. (1983) Synergism of the antimicrobial agents miconazole, bacitracin and polymyxin B. Chemotherapy, 29, 419-427.
38. Crackower, S.H.B. (1972) The effect of griseofulvin on mitosis in Aspergillus nidulans. Canadian Journal of Microbiology, 18, 683-687.
39. Daneshmend, T.K. & Warnock, D.W. (1988) Clinical pharmacokinetics of ketoconazole. Clinical Pharmacokinetics, 14, 13-34.
40. Daum, G., Lees, N.D., Bard, M. & Dickson, R. (1998) Biochemistry, cell biology and molecular biology of lipids of Saccharomyces cerevisiae. Yeast, 14, 1471-1510.
41. Davidse, L.C. & Flach, W. (1978) Interaction of thiabendazole with fungal tubulin. Biochimica and Biophysica Acta, 543, 82-90.
42. Davidse, L.C. & Ishii, H. (1995) Biochemical and molecular aspects of the mechanisms of action of benzimidazoles, N-phenylcarbamates and N-phenylformamidoximes and the mechanism of resistance to these compounds in fungi, In Modern Selective Fungicides. Ed. Lyr, H. pp. 305-322, Gustav Fischer Verlag, Jena.
43. De Backer, M.D., Ilyina, T., Ma, X.-J., Vandoninck, S., Luyten, W.H.M.L. & Vanden Bossche, H. (2001) Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA micro-array. Antimicrobial Agents and Chemotherapy, 45, 1660-1670.
44. De Carli, L. & Larizza, L. (1988) Griseofulvin. Mutation Research, 195, 91-126.
45. De Matteis, F. (1982) Loss of microsomal components in drug-induced liver damage, in cholestasis and after administration of chemicals which stimulate heme catabolism. In Hepatic Cytochrome P450 Monooxyganese System. Eds Schenkman, J.B. & Kupfer, D. pp. 307-340. Pergamon Press. Oxford.
46. De Nollin, S., Van Belle, H., Goosens, F., Thoné, F. & Borgers, M. (1977) Cytochemical and biochemical studies of yeasts after in vitro exposure to miconazole. Antimicrobial Agents and Chemotherapy, 11, 500-513.
47. Debruyne, D. & Coquerel, A. (2001) Pharmacokinetics of antifungal agents in onychomycoses. Clinical Pharmacokinetics, 40, 441-472.
48. Decottignies, A. & Goffeau, A. (1997) Complete inventory of the yeast ABC proteins. Nature Genetics, 15, 137-145.
49. Del Sorbo, G., Andrade, A.C., Van Nistelrooy, J.G.M., Van Fan, J.A.L., Balzi, E. & De Waard, M.A. (1997) Multidrug resistance in Aspergillus nidulans involves novel ATP-binding cassette transporters. Molecular and General Genetics, 254, 417-426.
50. Delp, C.J. (1995) Benzimidazole and related fungicides. In Modern Selective Fungicides. Ed. Lyr, H. pp. 291-303. Gustav Fischer Verlag, Jena.
51. Denning, D.W., Venkateswarlu, K., Oakley, K.L., Anderson, M.J., Manning, N.J., Stevens, D.A., Warnock, D.W. & Kelly, S.L. (1997) Itraconazole resistance in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 41, 1364-1368.
52. Desplenter, L. (1988) Aspergillosis in animal health: environmental control. In Aspergillus and Aspergillosis. Eds Vanden Bossche, H., Mackenzie, D.W.R. & Cauwenbergh, G. pp. 289-297. Plenum Press. New York.
53. Desplenter, L. & Van Cutsem, J. (1980) In vitro antifungal activity of parconazole (R39500). In Preclinical Research Report. Janssen Research Products Information Service. Ed. Cauwenbergh, G. pp. 289-297. Plenum Press, New York.
54. Dick, J.D., Merz, W.G. & Saral, R. (1980) Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrobial Agents and Chemotherapy, 18, 158-163.
55. Dick, J.D., Rosengard, B.R., Merz, W.G., Stuart, R.K., Hutchins, G.M. & Saral, R. (1985) Fatal disseminated candidiasis due to amphotericin B-resistant Candida guilliermondii. Annals of Internal Medicine, 102, 67-68.
56. Dupont, B, (2002) Overview of the lipid formulations of amphotericin B, Journal of Antimicrobial Chemotherapy. 49 (Suppl. S1), 31-36.
57. Dupont, B., Richardson, M., Verweij, P.E. & Meis, J.F.G.M. (2000) Invasive aspergillosis. Medical Mycology, 38 (Suppl. 1), 215-224.
58. Edlind, T.D., Henry, K.W., Metera, K.A. & Katiyar, S.K. (2001) Aspergillus fumigatus CYP51 sequence: potential basis for fluconazole resistance. Medical Mycology, 39, 299-302.
59. Elewski, B.E. (1998) Onychomycosis: pathogenesis, diagnosis, and management. Clinical Microbiology Reviews, 11, 415-429.
60. Ellis, D. (2002) Amphotericin B: spectrum and resistance. Journal of Antimicrobial Chemotherapy, 49 (Suppl. S1), 7-10.
61. Espine-Ingroff, A., Dawson, K., Pfaller, M. et al. (1995) Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrobial Agents and Chemotherapy, 39, 314-319.
62. Espinel-Ingroff, A., Warnock, D.W., Vaquez, J.A. & Arthington-Skaggs, B.A. (2000) In vitro antifungal susceptibility methods and clinical implications of antifungal resistance. Medical Mycology, 38 (Suppl. 1), 293-304.
63. Faergemann, J., Zehender, H. & Millerioux, L. (1994) Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clinical and Experimental Dermatology, 19, 121-126.
64. Favre, B. & Ryder, N.S. (1996) Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrobial Agents and Chemotherapy, 40, 443-447.
65. Favre, B. & Ryder, N.S. (1997) Characterization of squalene epoxidase activity from the pathogenic yeast Candida albicans. Gene, 189, 119-126.
66. Fernández-Torres, B., Carrillo, A.J., Martin, E., Del Palacio, A., Moore, M.K., Valverde, A., Serrano, M. & Guarro, J. (2001) In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrobial Agents and Chemotherapy, 45, 2524-2528.
67. Fernández-Torres, B., Vázquez-Veiga, H., Llovo, X., Pereiro, M., Jr & Guarro. J. (2000) In vitro susceptibility to itraconazole, clotrimazole, ketoconazole and terbinafine of 100 isolates of Trichophyton rubrum. Chemotherapy, 46, 390-394.
68. Fournier, I., Barwicz, J. & Tancredo, P. (1998) The structuring effects of amphotericin B on pure and ergosterol- or cholesterol-containing dipalmitoylphosphatidylcholine bilayers: a differential scanning calorimetry study. Biochimica Biophysica Acta, 1373, 76-86.
69. Fukushiro, R., Urabe, H., Kagawa, S., Watanabe, S., Takahashi, H., Takahashi, S. & Nakajima, H. (1992) Butenafine hydrochloride, a new antifungal agent: clinical and experimental study. In Recent Progress in Antifungal Chemotherapy. Eds Yamaguchi, H. & Kobayashi, G.S. & Takahashi, H. pp. 147-157. Marcel Dekker, Inc., New York.
70. Gabal, M.A. (1986) Study on the evaluation of the use of thiabendazole in the treatment and control of bovine dermatophytosis. Mycopathologia, 93, 163-168.
71. Galgiani, J.N. & Stevens, D.A. (1976) Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrobial Agents and Chemotherapy, 10, 721-726.
72. Gentles, J.C. (1956) Experimental ringworm in guinea pig: oral treatment with griseofulvin. Nature, 182, 476-477.
73. Georgopapadakou, N.H., Dix, B.A., Smith, S.A., Freudenberger, J. & Funke, P.T. (1987) Effect of antifungal agents on lipid biosynthesis and membrane integrity in Candida albicans. Antimicrobial Agents and Chemotherapy, 31, 46-51.
74. Godefroi, E.F., Heeres, J., Van Cutsem, J. & Janssen, P.A.J. (1969) The preparation and antimycotic properties of derivatives of 1-phenethy-limidazole. Journal of Medicinal Chemistry, 12, 784-791.
75. Goffeau, A., Park, J., Paulsen, I.T., Jonniaux, J.L., Dinh, T., Mordant, P. & Saier, M.H. (1997) Multidrug-resistant transport proteins in yeast: complete inventory and phylogenetic characterization of yeast open reading frames within the major facilitator superfamily. Yeast, 13, 43-54.
76. Goffeau, A. & Slayman, C.W. (1981) The proton translocating ATPase of the fungal plasma membrane. Biochimica Biophysica Acta, 639, 197-223.
77. Goldberg, J., Connolly, P., Schnizlein, C., Durkin, M., Kohler, S., Smedema, M., Brizendine, E., Hector, R. & Wheat, J. (2000) Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model. Antimicrobial Agents and Chemotherapy, 44, 1624-1629.
78. Granade, T.C. & Artis, W.M. (1980) Antimycotic susceptibility testing of dermatophytes in microcultures with a standardized fragmented mycelial inoculum. Antimicrobial Agents and Chemotherapy, 17, 725-729.
79. Groll, A.H., Petraitis, V., Petraitiene, R., Field-Ridley, A., Calendario, M., Bacher, J., Piscitelli, S.C. & Walsh, T.J. (1999) Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits. Antimicrobial Agents and Chemotherapy, 43, 2463-2467.
80. Groll, A.H., Wood, L., Roden, M., Mickiene, D., Chiou, C.C., Townley, E., Dad, L., Piscitelli, S.C. & Walsh, T.J. (2002) Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrobial Agents and Chemotherapy, 46, 2554-2563.
81. Gull, K. & Trinci, A.J.P. (1973) Griseofulvin inhibits fungal mitosis. Nature. 244, 292-294.
82. Gupta, A.K., Kohli, Y., Faergemann, J. & Summerbell, R.C. (2000) In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine. British Journal of Dermatology, 142, 758-765.
83. Gupta, A.K. & Summerbell, R.C. (2000) Tinea capitis, Medical Mycology, 38, 255-287.
84. Hall, M., Monka, C., Krupp, P. & O'Sullivan, D. (1997) Safety of oral terbinafine. Results of a postmarketing surveillance study in 25884 patients. Archives of Dermatology, 133, 1213-1219.
85. Hamilton-Miller, J.M.T. (1973) Chemistry and biology of the polyene macrolide antibiotics. Bacteriological Reviews, 37, 166-196.
86. Hammer, K.A., Carson, C.F. & Riley, T.V. (2000) In vitro activities of ketoconazole, econazole, miconazole, and Melaleuca alterifolia (tea tree) oil against Malassezia species. Antimicrobial Agents and Chemotherapy, 44, 467-469.
87. Harousseau, J.L., Dekker, A.W., Stamatoullas-Bastard, A. et al. (2000) Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrobial Agents and Chemotherapy, 44, 1887-1893.
88. Hazen, E.L. & Brown, R. (1950) Two antifungal agents produced by a soil actinomycete. Science, 112, 423.
89. Heel,. R.C. (1982) Ketoconazole: pharmacological profile. In Ketoconazole in the Management of Fungal Disease. Eds Drouhet, E., Hay, R.J., Jones, H.E. & Restrepo, A. pp. 55-77. ADIS Press, New York.
90. Heeres, J., Backx, L.J.J., Mostmans, J.H. & Van Cutsem, J. (1979) Antimycotic imidazoles. Part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent. Journal of Medicinal Chemistry, 22, 1003-1005.
91. Hennequin, C., Benailly, N., Silly, C., Sorin, M., Scheinmann, P., Lenoir, C., Gatllard, J.L. & Berche, P. (1997) In vitro susceptibility to amphotericin B, itraconazole, and miconazole in filamentous fungi isolated from patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy, 41, 2064-2066.
92. Heykants, J., Michiels, M., Meuldermans, W., Monbaliu, J., Lavrijsen, K., Van Peer, A., Levron, J.C., Woestenborghs, R. & Cauwenbergh, G. (1987) The pharmacokinetics of itraconazole in animals and men: an overview. In Recent Trends in the Discovery and Evaluation of Antifungal Agents. Ed. Fromtling, R.A. pp. 223-249. J.R. Prous Science Publishers S.A., Barcelona.
93. Heykants, J., Van Peer, A., Van de Velde, V., Van Rooy, P., Meuldermans, W., Lavrijsen, K., Woestenborghs, J., Van Cutsem, J. & Cauwenbergh, G. (1989) The clinical pharmacokinetics of itraconazole: an overview. Mycoses. 32 (Suppl. 1), 67-87.
94. Hide, C.A., Read, P.J. & Hall, S.M. (1992) Resistance to thiabendazole in Fusarium species isolated from potato tubers affected by dry rot. Plant Pathology, 41, 745-748.
95. Hitchcock, C.A. (1991) Cytochrome P450-dependent 14α-sterol demethylase of Candida albicans and its interaction with azole antifungals. Biochemical Society Transactions, 19, 782-787.
96. Hitchcock, C.A. & Whittle, P.J. (1993) Chemistry and mode of action of fluconazole. In Cutaneous Antifungal Agents. Eds Rippon, J.W. & Fromtling, R.A. pp. 183-197. Marcel Dekker, Inc., New York.
97. Hollomon, D.W., Butters, J.A., Barker, H. & Hall, L. (1998) Fungal β-tubulin as a fusion protein, binds benzimidazole and phenylcarbamate fungicides. Antimicrobial Agents and Chemotherapy, 42, 2171-2173.
98. Horsburgh, C.R., Jr & Kirkpatrick, C.H. (1983) Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. American Journal of Medicine, 74 (Suppl. 1B), 23-29.
99. 2O. Protoplasma, 92, 195-210.
100. Howard, R.J. & Aist, J.R. (1980) Cytoplasmic microtubules and fungal morphogenesis: ultrastructural effects of methyl-benzimidazol-2yl carbamate determined by freeze-substitution of hyphal tip cells. Journal of Cellular Biology, 87, 55-64.
101. Hubbard, M.J., Surarit, T.R., Sullivan, P.A. & Shepherd, M.G. (1986) The isolation of plasma membrane and characterisation of the plasma membrane ATPase from the yeast Candida albicans. European Journal of Biochemistry, 154, 375-381.
102. Iverson, S.L. & Uetrecht, J.P. (2001) Identification of a reactive metabolite of terbinafine; insights into terbinafine-induced hepatotoxicity. Chemical Research in Toxicology, 14, 175-181.
103. de Jaham, C., Paradis, M. & Papich, M.G. (2000) Antifungal dermatologic agents: azoles and allylamines. Compendium on Continuing Education for the Practicing Veterinarian, 22, 548-559.
104. Jessup, C.J., Warner, J., Isham, N., Hasan, I. & Ghannoum, M.A. (2000a) Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. Journal of Clinical Microbiology, 38, 341-344.
105. Jessup, C.J., Ryder, N.S. & Ghannoum, M.A. (2000b) An evaluation of the in vitro activity of terbinafine. Medical Mycology, 38, 155-159.
106. Johnson, E.M., Ojwang, J.O., Szekely, A., Wallace, T.L. & Warnock, D.W. (1998) Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrobial Agents and Chemotherapy, 42, 1412-1416.
107. Johnson, E.M., Warnock, D.W., Luker, J., Porter, S.R. & Scully, C. (1995) Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. Journal of Antimicrobial Chemotherapy, 35, 103-114.
108. Kakeya, H., Miyazaki, Y., Miyazaki, H., Nyswaner, K., Grimberg, B. & Bennett, J.E. (2000) Genetic analysis of azole resistance in the Darlington strain of Candida albicans. Antimicrobial Agents and Chemotherapy, 44, 2985-2990.
109. Katiyar, S.K. & Edlind, T.D. (2001) Identification and expression of multidrug resistance-related ABC transporter genes in Candida krusei. Medical Mycology, 39, 109-116.
110. Kaukonen, K.M., Olkkola, K.T. & Neuvonen, P.J. (1998) Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. European Journal of Clinical Pharmacology, 53, 445-449.
111. Kelly, S.L., Lamb, D.C., Baldwin, B.C., Corran, A.J. & Kelly, D.E. (1997a) Characterization of Saccharomyces cerevisiae CYP61, sterol Δ22-desaturase, and inhibition by azole antifungal agents. Journal of Biological Chemistry, 272, 9986-9988.
112. Kelly, S.L., Lamb, D.C. & Kelly, D.E. (1999a) Y132H substitution in Candida albicans sterol 14α-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiology Letters, 180, 171-175.
113. Kelly, S.L., Lamb, D.C., Kelly, D.E., Mannung, N.J., Löffler, J., Hebart, H., Schumacher, U. & Einsele, H. (1997b) Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDs patients caused by defective sterol delta 5.6-desaturation. FEBS Letters, 400, 80-82.
114. Kelly, S.L., Lamb, D.C., Loeffler, J., Einsele, H. & Kelly, D.E. (1999b) The G464S amino acid substitution in Candida albicans sterol 14α-demethylase causes fluconazole resistance in the clinic through reduced affinity. Biochemical Biophysical Research Communications, 262, 174-179.
115. Kerridge, D. & Whelan, W.L. (1984) The polyene macrolide antibiotics and 5-fluorocytosine: molecular actions and interactions. In Mode of Action of Antifungal Agents. Eds Trinci, A.P.J. & Ryley, J.F. pp. 343-375. Cambridge University Press, Cambridge.
116. Klepser, M.E., Ernst, E.J. & Pfaller, M.A. (1997) Update on antifungal resistance. Trends in Microbiology, 5, 372-375.
117. Kollar, R., Petrakova, E., Ashwell, G., Robbins, P.W. & Cabib, E. (1995) Architecture of the yeast cell wall. The linkage between chitin and β (1-3) -glucan. Journal of Biological Chemistry, 270, 1170-1178.
118. Kollias, G.V., Palgut, J. & Ross, J. (1986) The use of ketoconazole in birds: prelimimirary pharmacokinetics and clinical applications. Proceedings of the Annual Meeeting of the Association of Avian Veterinarians, Miami. USA, pp. 103-104.
119. Korting, H.C., Ollert, M. & Abeck, D. and the German collaborative dermathophyte drug susceptibility Study Group (1995) Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. Antimicrobial Agents and Chemotherapy, 39, 1206-1208.
120. Kwa, M.S.G., Veenstra, J.G., van Dujk, M. & Roos, M.H. (1995) β-Tubulin genes from the parasitic nematode Haemonchus contortus modulate drug resistance in Caenorhabditis elegans. Journal of Molecular Biology, 246, 500-510.
121. Lamb, D.C., Kelly, D.E., Baldwin, B.C. & Kelly, S.L. (2000a) Differential inhibition of human CYP3A4 and Candida albicans CYP51 with azole antifungal agents. Chemical Biological Interactions, 125, 165-175.
122. Lamb, D.C., Kelly, D., Schunck, W.H., Shyadehi, A.Z., Akhtar, M., Lowe, D.J., Baldwin, B.C. & Kelly, S.L. (1997) The mutation T315A in Candida albicans sterol 14α-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. Journal of Biological Chemistry, 272, 5682-5688.
123. Lamb, D.C., Kelly, D.E., White, T.C. & Kelly, S.L. (2000b) The R464K amino acid substitution in Candida albicans sterol 14α-demethylase causes drug resistance through reduced affinity. Antimicrobial Agents and Chemotherapy, 44, 63-67.
124. Lampo, A., De Beule, K., Cauwenbergh, G. & Van Cauteren, H. (1993) Safety of itraconazole in animals and humans. In Cutaneous Antifungal Agents. Eds Rippon, J.W. & Fromtling, R.A. pp. 285-293. Marcel Dekker, Inc., New York.
125. Langcake, P., Kuhn, P.L. & Wade, M. (1983) The mode of action of systemic fungicides. In Progress in Pesticide Biochemistry and Toxicology, Vol. 3. Eds Hutson, D.H. & Roberts, T.R. pp. 1-109. Wiley, Chichester.
126. Latrille, F., Charuel, C. & Lodola, A. (1989) A comparative study of the effects of ketoconazole and fluconazole on 17β-estradiol production by rat ovaries in vitro. Research Communications in Chemical Pathology and Pharmacology, 64, 173-176.
127. Lefebvre, R.A., Van Peer, A. & Woestenborghs. R. (1997) Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. British Journal of Clinical Pharmacology, 43, 319-322.
128. Levron, J.C., Stephan, P. & Razanamiraka, G. (1985) Pharmacoktnetic study of parconazole, antifungal drug, in guinea fowl. Third EAVPT Congress, Ghent, Belgium, Session 9, p. 120.
129. Li, R.K., Ciblak, M.A., Nordoff, N., Pasarell, L., Warnock, D.W. & McGinnis, M.R. (2000) In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis. Coccidioides immitis, and Histoplasma capsulatum. Antimicrobial Agents and Chemotherapy, 44, 1734-1736.
130. 14C-griseofulvin in man. Journal of Pharmacology and Experimental Therapeutics, 187, 415-422.
131. Llop, C., Pujol, I., Aguilar, C., Sala, J., Riba, D. & Guarro, J. (2000) Comparison of three methods of determining MICs for filamentous fungi using different end point criteria and incubation methods. Antimicrobial Agents and Chemotherapy, 44, 239-242.
132. Löffler, J., Kelly, S.L., Hebart, H., Schumacher, U., Lass-Flörl, C. & Einsele, H. (1997) Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiology Letters, 151, 263-268.
133. Löpez-Ribot, J.L., McAtee, R.K., Perea, S., Kirkpatrick, W.R., Rinaldi, M.G. & Patterson, T.F. (1999) Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy, 43, 1621-1630.
134. Lorenzini R., Mercantini, R. & De Bernardis, F. (1985) In vitro sensitivity of Malassezia spp. to various antimycotics. Drugs and Experimental Clinical Research, 11, 393-395.
135. Lyons, C.N. & White, T.C. (2000) Transcriptional analyses of antifungal drug resistance in Candida albicans. Antimicrobial Agents and Chemotherapy, 44, 2296-2303.
136. Marichal, P. (1999) Mechanisms of resistance to azole antifungal compounds. Current Opinion in Anti-Infective Investigational Drugs, 1, 318-333.
137. Marichal, P., Gorrens, J., Coene, M.-C., Le Jeune, L. & Vanden Bossche, H. (1995) Origin of differences in susceptibility of Candida krusei to azole antifungal agents. Mycoses, 38, 111-117.
138. Marichal, P., Gorrens, J., Laurijssens, L., Vermuyten, K., Van Hove, C., Le Jeune, L., Verhasselt, P., Sanglard, D., Borgers, M., Ramaekers, F.C., Odds, F. & Vanden Bossche, H. (1999a) Accumulation of 3-ketosteroids induced by itraconazole in azole resistant clinical Candida albicans isolates. Antimicrobial Agents and Chemotherapy, 43, 2663-2670.
139. Marichal, P., Gorrens, J. & Vanden Bossche, H. (1985) The action of itraconazole and ketoconazole on growth and sterol synthesis in Aspergillus fumigatus and Aspergillus niger. Sabouraudia: Journal of Medical and Veterinary Mycology, 23, 13-21.
140. Marichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P., Luyten, W., Borgers, M., Ramaekers, F.C.S., Odds, F.C. & Vanden Bossche, H. (1999b) Contribution of mutations in the cytochrome P450 14α-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology, 145, 2701-2713.
141. Marichal, P., Vanden Bossche, H., Odds, F.C., Nobels, G., Warnock, D.W., Timmermans, V., Van Broekhoven, C., Fay, S. & Mose-Larsen, P. (1997) Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrobial Agents and Chemotherapy, 41, 2229-2237.
142. Marr, K., Lyons, C.N., Rustad, T., Bowden, R.A. & White, T. (1998) Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrobial Agents and Chemotherapy, 42, 2584-2589.
143. McGinnis, M.R., Nordoff, N., Li, R.-K., Pasarell, L. & Warnock, D.W. (2001) Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B. Medical Mycology, 39, 369-371.
144. Mehta, R.T., Hopfer, R.L., McQueen, T., Juliano, R.L. & Lopez-Berestein, G. (1987) Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrobial Agents and Chemotherapy, 31, 1901-1903.
145. Meletiadis, J., Meis, J.F.G.M., Mouton, J.W., Donnelly, J.P. & Verweij, P.E. (2000) Comparison of NCCLS and 3-(4,5-dimethyl-2-thiazyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. Journal of Clinical Microbiologyy, 38, 2949-2954.
146. Mercer, E.I. (1991) Sterol biosynthesis inhibitors: their current status and modes of action. Lipids. 26, 584-597.
147. Mieth, H. (1993) In vitro and in vivo activities of terbinafine. In Cutaneous Antifungal Agents. Eds Rippon, J.W. & Fromtling, R.A. pp. 137-149. Marcel Dekker, Inc., New York.
148. Miyazaki, H., Miyazaki, Y., Geber, A., Parkinson, T., Hitchcock, C., Falconer, D.J., Ward, J., Marsden, K. & Bennett, J.E. (1998) Fluconazole resistance associated with drug efflux and increased transcription of a drug transporter gene. PDH1 in Candida glabrata. Antimicrobial Agents and Chemotherapy, 42, 1695-1701.
149. Moore, C.B., Walls, C.M. & Denning, D.W. (2000) In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrobial Agents and Chemotherapy, 44, 441-443.
150. Moore, C.B., Walls, C.M. & Denning, D.W. (2001) In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B. Antimicrobial Agents and Chemotherapy, 45, 1882-1885.
151. Morace, G., Sanguinetti, M., Posteraro, B. & Pagano, L. (1995) In vitro susceptibility of Candida species isolated from patients with haematological malignancies. Mycoses, 38, 59-67.
152. Moran, G.P., Sanglard, D., Donelly, S.M., Shanley, D.B., Sullivan, D.J. & Coleman, D.C. (1998) Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrobial Agents and Chemotherapy, 42, 1819-1830.
153. Mosquera, J. & Denning, D.W. (2002) Azole cross-resistance in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 46, 556-557.
154. Muto, N., Hirai, H., Tanaka, T., Itoh, N. & Tanaka, K. (1997) Induction and inhibition of cytochrome P450 isoforms by imazalil, a food contaminant, in mouse small intestine and liver. Xenobiotica, 27, 1215-1223.
155. National Committee for Clinical Laboratory Standards (1992) Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeast. Proposed standard. Document M27-P. National Committee for Laboratory Standards, Wayne, PA.
156. National Committee for Clinical Laboratory Standards (1998) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium - Forming Filamentous Fungi. Proposed standard M38-P. National Committee for Clinical Laboratory Standards, Wayne, PA.
157. Niewerth, M., Splanemann, C., Korting, H.C., Ring, J. & Abeck, D. (1998) Anttmicrobial susceptibility testing of dermatophytes-comparison of the agar macrodilution and broth microdilution tests. Chemotherapy, 44, 31-35.
158. Nogales, E. (1999) A structural view of microtubule dynamics. Cellular and Molecular Life Sciences, 56, 133-142.
159. Nozawa, Y. & Morita, T. (1992) Biochemical aspects of squalene epoxidase inhibition by a thiocarbamate derivative, naphthiomate T. In Recent Progress in Antifungal Chemotherapy, Eds Yamaguchi, H., Kobayashi, G.S & Takahashi, H. pp. 53-64. Marcel Dekker, Inc., New York.
160. Oakley, B.R. & Morris, N.R. (1980) Nuclear movement is β-tubulin dependent in Aspergillus nidulans. Cell. 19, 255-262.
161. Odds, F.C. (1998) Should resistance to azole antifungals in vitro be interpreted as predicting clinical non-response? Drug Resistance Updates, 1, 11-15.
162. Odds, F.C. & Vanden Bossche, H. (2000) Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. Journal of Antimicrobial Chemotherapy, 45, 371-373.
163. Odds, F.C. Vranckx, L. & Woestenborghs, F. (1995) Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrobial Agents and Chemotherapy, 39, 2051-2060.
164. Odds, F.C. (1996) Antifungal therapy. In Principles and Practice of Clinical Mycology. Eds Kibbler, C.C., Mackenzie, D.W.R & Odds, F.C. pp. 35-48. John Wiley & Sons, Chichester.
165. Okey, A.B., Roberts, E.A., Harper, P.A. & Denison, M.S. (1986) Induction of drug matabolising enzymes: mechanisms and consequences. Clinical Biochemistry, 19, 132-141.
166. Osterloh, I,H, & Pluck, N.D. (1993) Safety of fluconazole. In Cutaneous Antifungal Agents. Eds Rippon, J,W, & Fromtling, R.A. pp. 215-229. Marcel Dekker, Inc., New York.
167. Oxford, A.E., Raistrick, M. & Simonart, P. (1939) Studies in biochemistry of micro-organisms. LX Griseofulvin C17H1606C1 metabolic product of Penicillium griseofulvin, Dierckx. Biochemical Journal, 33, 240-248.
168. Pelletier, R., Peter, J., Antin, C., Gonzalez, C., Wood, L. & Walsh, T.J. (2000) Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: in vitro and clinical correlations. Journal of Clinical Microbiology, 38, 1563-1568.
169. Perea, S., Fothergill, A.W., Sutton, D.A. & Rinaldi, M.G. (2001a) Comparison of in vitro activities of vortconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method. Journal of Clinical Microbiology, 39, 385-388.
170. Perea, S., López-Ribot, J.L., Kirckpatrick, W.R., McAtee, R.K., Santillán, R.A., Martinez, M., Calabrese, D., Sanglard, D. & Patterson, T.F. (2001b) Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy, 45, 2676-2684.
171. Perparim, K., Nagai, H., Hashimoto, A., Goto, Y., Tashiro, T. & Nasu, M. (1996) In vitro susceptibility of Trichosporon beigelii to antifungal agents. Journal of Chemotherapy, 8, 445-448.
172. Pershing, L.K., Corlett, J. & Jorgensen, C. (1994) In vivo pharmacokinetics and pharmacodynamics of topical ketoconazole and miconazole in human stratum corneum. Antimicrobial Agents and Chemotherapy, 38, 90-95.
173. Pesti, M., Campbell, J.M. & Peberdy, J.F. (1981) Alteration of ergosterol content and chitin synthase activity in Candida albicans. Current Microbiology, 5, 187-190.
174. Peyron, F., Favel, A., Michel-Nguyen, A., Gilly, M., Regli, P. & Bolmstrom, A. (2001) Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest. Journal of Clinical Microbiology, 39, 339-342.
175. Pfaller, M.A., Messer, S.A., Boyken, L., Huynh, H., Hollis, R.J. & Diekema, D.J. (2002) In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp. global assessment of primary resistance using national committee for clinical laboratory standards susceptibility testing methods. Antimicrobial Agents and Chemotherapy, 46, 3518-3521.
176. Pfaller, M.A., Messer, S.A. & Hollis, R.J. (1994) Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae. Diagnostic Microbiology and Infectious Diseases, 20, 127-133.
177. Pfaller, M.A., Messer, S.A., Hollis, R.J. & Jones, R.N. (2001) In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. & Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy, 45, 2862-2864.
178. Pier, A.C., Cabães, F.J., Chermette, R., Ferreiros, L., Guillot, J., Jensens, H.E. & Santurio, J.M. (2000) Prominent animal mycoses from various regions of the world. Medical Mycology, 38 (Suppl. 1), 47-58.
179. Plempel, M., Berg, D., Büchel, K.H. & Ritter, W. (1988) Experimental antimycotic activity of azole derivatives - experience, knowledge and questions. In Sterol Biosynthesis Inhibitors. Eds Berg, D. & Plempel, M. pp. 349-396. Ellis Horwood Ltd, Chichester.
180. Plempel, M., Bartmann, K., Büchel, K.H. & Regel, E. (1969) Experimentelle Befunde über eines neues oral wirksames Antimykoticum mit breiten Wirkungsspecktrum. Deutsche Medizinische Wochenschrift, 94, 1356-1364.
181. Pohjola-Sintonen, S., Viitasalo, M., Toivonen, L. & Neuvonen, P. (1993) Itraconazole prevents terbinafine metabolism and increases risk of torsades de pointes ventricular tachycardia. European Journal of Clinical Pharmacology, 45, 191-193.
182. Polak, A. (1990) Mode of action studies. In Chemotherapy of Fungal Diseases. Ed. Ryley, J.F. pp. 153-182, Springer Verlag, Berlin.
183. Polak, A. (1992) 5-Fluorocytosine and its combination with other antifungal agents. In Recent Progress in Antifungal Chemotherapy. Eds Yamaguchi, H. & Kobayashi, G.S. & Takahashi, H. pp. 77-85. Marcel Dekker, Inc., New York.
184. Polak, A. & Dixon, D.M. (1987) Antifungal activity of amorolfine (Ro 14-4767/002) in vitro and in vivo. In Recent Trends in the Discovery and Evaluation of Antifungal Agents. Ed. Fromtling, R.A. pp. 555-573. J.R. Prous Science Publishers S.A., Barcelona.
185. Polak, A. & Hartman, P.G. (1991) Antifungal chemotherapy. Are we winning? Progress in Drug Research, 37, 191-269.
186. Polak, A. & Scholer, H.J. (1980) Mode of action of 5-fluorocytosine. Revue Institut Pasteur Lyon, 13, 233-244.
187. Prasad, R., De Wergifosse, P., Goffeau, A. & Balzi, E. (1995) Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Current Genetics, 27, 320-329.
188. Pye, G.W. & Marriott, M.S. (1982) Inhibition of sterol C-14-demethylation by imidazole containing antifungals. Sabouraudia, 20, 325-329.
189. Raab, W.P. (1972) Natamycin (Pimaricin) its Properties and Possibilities in Medicine. George Thieme Publishers. Stuttgart.
190. Raab, W.P. (1978) Mykosebehandlung mit imidazole derivaten, p. 41. Springer-Verlag, Berlin.
191. +-ATPase. Analytical Biochemistry, 173, 251-264.
192. Readio, J.D. & Bittman, R. (1982) Equilibrium binding of amphotericin B and its methyl ester and borate complex to sterols. Biochimica Biophysica Acta, 685, 219-224.
193. Redig, P.T. & Duke, G.E. (1985) Comparative pharmacokinetics of antifungal drugs in domestic turkeys, red tailed hawks, broad-winged hawks, and great-horned owls. Avian Diseases, 29, 649-661.
194. Reuben, A., Anaissie, E., Nelson, P.E., Hashem, R., Legrand, C., Ho, D.H. & Bodey, G.P. (1989) Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrobial Agents and Chemotherapy, 33, 1647-1649.
195. Rex, J.H., Phaller, M.A., Galgiani, J.N. et al. (1997) Development of interpretative breakpoints for antffungal susceptibility testing: conceptual framework and analysis of in vitro- in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clinical Infectious Diseases, 24, 235-247.
196. Rex, J.H., Rinaldi, M.G. & Pfaller, M.A. (1995) Resistance of Candida species to fluconazole. Antimicrobial Agents and Chemotherapy, 39, 1-8.
197. Rotowa, N.A., Shadomy, H.J. & Shadomy, S. (1990) In vitro activities of polyene and imidazole antifungal agents against unusual opportunistic fungal pathogens. Mycoses, 33, 203-211.
198. Ruhnke, M., Eigler, A., Tennagen, I., Geiseler, B., Engelmann, E. & Trautmann, M. (1994) Emergence of fluconazole-resistant strains in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. Journal of Clinical Microbiology, 32, 2092-2098.
199. Ryder, N.S. (1988) Mechanism of action and biochemical selectivity of allylamine antimycotic agents. Annals of the New York Academy of Sciences, 544, 208-220.
200. Ryder, N.S., Frank, L & Dupont, M.C. (1986) Ergosterol biosynthesis inhibition by the thiocarbamate antifungal agents, tolnaftate and tolciclate. Antimicrobial Agents and Chemotherapy, 29, 858-860.
201. Ryder, N.S. & Mieth, H. (1992) Allylamine antifungal drugs. Current Topics in Medical Mycology, 4, 158-188.
202. Ryder, N.S., Stuetz, A. & Nussbaumer, P. (1992) Squalene epoxidase inhibitors. Structural determinants for activity and selectivity of allylamines and related compounds. In Regulation of Isopentenoid Metabolism. Eds Nes, W.D., Parish, E.J. & Trzaskos, J.M. pp. 192-204. American Chemical Society, Washington, DC.
203. Ryley, J.F., Wilson, R.G. & Barrett-Bee, K.J. (1984) Azole resistance in Candida albicans. Sabouraudia, 22, 53-93.
204. Ryley, J.F., Wilson, R.G., Gravestock, M.B. & Poyser, J.P. (1981) Experimental approaches to antifungal chemotherapy. Advances in Pharmacology and Chemotherapy, 18, 49-176.
205. Sanglard, D., Ischer, F. & Bille, J. (2000) Mitochondrial loss is associated with high frequency azole resistance (HFAR) and with upregulation of the ABC-transporter genes CgCDR1 and CgCDR2 in Candida Glabrata. Abstract, 40th ICAAC, Toronto. Presentation Number 1954.
206. Sanglard, D., Ischer, F. & Bille, J. (2001) Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrobial Agents and Chemotherapy, 45, 1174-1183.
207. Sanglard, D., Ischer, F., Calabrese, D., de Micheli, M. & Bille, J. (1998a) Multiple resistance mechanisms to azole antifungals in yeast clinical isolates. Drug Resistance Updates, 1, 255-265.
208. Sanglard, D., Ischer, F., Koymans, L. & Bille, J. (1998b) Amino acid substitutions in the cytochrome P450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrobial Agents and Chemotherapy, 42, 241-253.
209. Sanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P.A. & Bille, J. (1999) The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrobial Agents and Chemotherapy, 43, 2753-2765.
210. Sanglard, D., Ischer, F., Monod, M. & Bille, J. (1997) Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterisation of CDR2, a new multidrug ABC transporter gene. Microbiology, 143, 405-416.
211. Sanglard, D., Isher, F., Monod, M. & Bille, J. (1996) Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrobial Agents and Chemotherapy, 40, 2300-2305.
212. Sanglard, D., Kuchler, K., Ischer, F., Pagani, L., Monod, M. & Bille, J. (1995) Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrobial Agents and Chemotherapy, 39, 2378-2386.
213. Sanglard, D. & Odds, F.C. (2002) Resistance of Candida species to antifungal agents; molecular mechanisms and clinical consequences. Lancet Infectious Diseases, 2, 73-85.
214. Sarosi, G.A. (1990) Amphotericin B still the 'gold standard' for antifungal therapy. Postgraduate Medicine, 88, 151-166.
215. Schmidt, A. (1997) In vitro activity of climbazole, clotrimazole and silver-sulphadiazine against isolates of Malassezia pachydermatis. Zentralblatt für Veterinarmedizin, 44, 193-197.
216. Shadomy, S. & Espinel-Ingroff, A. (1974) Susceptibility testing of antifungal agents. In Manual of Clinical Microbiology, 2nd edn. Eds Lennette, E.H., Spaulding, E.H. & Truant, J.P. pp. 569-574. American Society for Microbiology, Washington, DC.
217. Shadomy, S., White, S.C. & Dismukes, W.E. (1985) Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole. Journal of Infectious Diseases, 152, 1249-1256.
218. Siegel, M.R. & Ragsdale, N.N. (1978) Antifungal mode of action of imazalil. Pesticide Biochemistry and Physiology, 9, 48-56.
219. Smith, K.J., Warnock, D.W., Kennedy, C.T.C., Johnson, E.M., Hopwood, V., Van Cutsem, J. & Vanden Bossche, H. (1986) Azole resistance in Candida albicans. Journal of Medical and Veterinary Mycology, 24, 131-142.
220. +-ATPase, an antifungal target in Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy, 44, 2349-2355.
221. Spitzer, S.G. & Spitzer, E.D. (1997) Identification of a Cryptococcus neoformans sequence belonging to the major facilitator superfamily (MFS). Program and Abstracts of the 97th General Meeting of ASM. Abstract F26.
222. Stevens, D.A. (1999) Itraconazole in cyclodextrin solution. Pharmacotherapy, 19, 603-611.
223. Stevens, D.A. & Holmberg, K. (1999) Resistance to antifungal drugs: current status and clinical implications. Current Opinion in Anti-Infective Investigational Drugs, 1, 306-317.
224. Stevens, D.A. & Stevens, J.A. (1996) Cross-resistance phenotypes of fluconazole-resistant Candida species: results with 655 clinical isolates with different methods. Diagnostic Microbiology and Infectious Diseases, 26, 145-148.
225. Stütz, A. (1988) Synthesis and structure-activity correlations within allylamine antimycotics. Annals of the New York Academy of Sciences, 544, 46-62.
226. Suzuki, S., Kurata, N., Nishimura, Y., Yasuhara, H. & Satoh, T. (2000) Effects of imidazole antimycotics on the liver microsomal cytochrome P450 isoforms in rats: comparison of in vitro and ex vivo studies. European Journal of Drug Metabolism and Pharmacokinetics, 25, 121-126.
227. Thienpont, D., Van Cutsem, J., Van Cauteren, H. & Marsboom, R. (1981) The biological and toxicological properties of imazalil. Arzeimittel-Forschung, 31, 309-315.
228. Thienpont, D., Van Cutsem, J., Van Gerven, F., Heeres, J. & Janssen, P.A. (1979) Ketoconazole - a new broad spectrum orally active antimycotic. Experientia, 35, 606-607.
229. Thienpont, D., Van Cutsem, J., Van Nueten, J.M., Niemegeers, C.J.E. & Marsboom, R. (1975) Biological and toxicological properties of econazole, a broad spectrum antimycotic. Arzeimittel-Forschung, 25, 224-230.
230. Thomas, P.A. & Rajasekaran, J. (1988) Treatment of Aspergillus keratitis with imidazole and related compounds. In Aspergillus and Aspergillosis. Eds Vanden Bossche, H., Mackenzie, D.W.R. & Cauwenbergh, G. pp. 267-279. Plenum Press, New York.
231. Thornewell, S.J., Peery, T.J. & Skatrud, P.L. (1997) Cloning and characterization of CneMDR1: a Cryptococcus neoformans gene encoding a protein related to multidrug resistance proteins. Gene. 201, 21-29.
232. Tobin, M.B., Peery, R.B. & Skatrud, P.L. (1997) Genes encoding multiple drug resistance like proteins in Aspergillus fumigatus and Aspergillus flavus. Gene, 200, 11-23.
233. Troke, P. (1993) In vitro and experimental in vivo activities of fluconazole against some fungi causing cutaneous mycoses. In Cutaneous Antifungal Agents. Eds Rippon, J.W. & Fromtling. R.A. pp. 199-214. Marcel Dekker, Inc., New York.
234. Uchida, Y., Onodera, S., Nakade, T. & Otomo, K. (1994) Sterol composition in polyene antibiotic-sensitive and resistant strains of Malassezia pachydermatis. Veterinary Research Communications, 18, 183-187.
235. Vaden, S.L., Heit, M.C., Hawkins, E.C., Manough, C. & Riviere, J.E. (1997) Fluconazole in cats: pharmacokinetics following intravenous and oral administration and penetration into cerebrospinal fluid, aqeuous humour and pulmonary epithelial lining fluid. Journal of Veterinary Pharmacology and Therapeutics, 20, 181-186.
236. Van Cutsem, J. & Janssen, P.A.J. (1988) In vitro and in vivo models to study the activity of antifungals against Aspergillus. In Aspergillus and Aspergillosis. Eds Vanden Bossche, H., Mackenzie, D.W.R. & Cauwenbergh, G. pp. 215-227. Plenum Press. New York.
237. Van Cutsem, J. & Thienpont, D. (1972) Miconazole, a broad-spectrum antimycotic agent with antibacterial activity. Chemotherapy, 17, 392-404.
238. Van Cutsem, J., Van Gerven, F., Geerts, H. & Rochette, F. (1985) Treatment with enilconazole spray of dermatophytosis in rabbit farms. Mycosen, 28, 400-407.
239. Van Cutsem, J., Van Gerven, F. & Janssen, P.A.J. (1986) The in vitro activity of azoles. In In Vitro and in Vivo Evaluation of Antifungal Agents. Eds Iwata, K. & Vanden Bossche, H. pp. 51-64. Elsevier Science Publishers B.V., Amsterdam.
240. Van Gerven, F. & Odds, F.C. (1995) The anti- Malassezia furfur activity in vitro and its experimental dermatitis of six imidazole antifungal agents: bifonazole, clotrimazole, flutrimazole, ketoconazole, miconazole and sertaconazole. Mycoses, 38, 389-393.
241. Van Gestel, J. (1986) The vapour phase activity of antifungal compounds: a neglected or a negligible phenomenon? In In Vitro and in Vivo Evaluation of Antifungal Agents. Eds Iwata, K. & Vanden Bossche, H, pp. 207-218. Elsevier Science Publishers B.V., Amsterdam.
242. Van Gestel, J. Van Cutsem, J. & Thienpont, D. (1981) Vapour phase activity of imazalil. Chemotherapy, 27, 270-276.
243. Vanden Bossche, H. (1985) Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. Current Topics in Medical Mycology, 1, 313-351.
244. Vanden Bossche, H. (1988) Mode of action of pyridine, pyrimidine and azole antifungals. In Sterol Biosynthesis Inhibitors. Eds Berg. D. & Plempel, M. pp. 79-119. Ellis Horwood Ltd, Chichester.
245. Vanden Bossche, H. (1990) Importance and role of sterols in fungal membranes. In Biochemistry of Cell Walls and Membranes in Fungi. Eds Kuhn, P.J., Trinci, A.PJ., Jung, M.J., Goosey, M.W. & Copping, L.G. pp. 135-157. Springer-Verlag. Berlin.
246. Vanden Bossche, H. (1991) Anti-candida drugs - mechanisms of action. In Candida and Candidamycoses. Eds Tümbay, E., Seelinger, H.P.R. & Ozdem, A. pp. 83-95. Plenum Press, New York.
247. Vanden Bossche, H. (1992) Inhibitors of P450-dependent steroid biosynthesis: from research to medical treatment. Journal of Steroid Biochemistry and Molecular Biology, 43, 1003-1021.
248. Vanden Bossche, H. (1995) Chemotherapy of human fungal infections. In Modern Selective Fungicides. Ed. Lyr. H. pp. 432-484. Gustav Fischer Verlag, Jena.
249. Vanden Bossche, H. (1997) Mechanisms of antifungal resistance. Revista Iberoamericano Micología, 14, 44-49.
250. Vanden Bossche, H., Bellens, D., Cools, W. et al. (1986) Cytochrome P450: target for itraconazole. Drug Development Research, 8, 287-298.
251. Vanden Bossche, H., Dromer, F., Improvisi, I., Lozano-Chiu, M., Rex, J.H. & Sanglard, D. (1998) Antifungal drug resistance in pathogenic fungi. Medical Mycology. 36 (Suppl. 1), 119-128.
252. Vanden Bossche, H., Heeres, J., Backx, L.J.J., Marichal, P. & Willemsens, G. (1993a) Discovery, chemistry, mode of action, and selectivity of itraconazole. In Cutaneous Antifungal Agents. Eds Rippon, J.W. & Fromtling, R.A: pp. 263-283. Marcel Dekker, Inc., New York.
253. Vanden Bossche, H. & Koymans, L. (1998) Cytochromes P450 in fungi. Mycoses, 41 (Suppl. 1), 32-38.
254. Vanden Bossche, H., Koymans, L. & Moereels, H. (1995) P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacology and Therapeutics, 67, 79-100.
255. Vanden Bossche, H., Lauwers, W., Willemsens, G., Marichal, P., Cornelissen, F. & Cools, W. (1984) Molecular basis for the antimycotic and antibacterial activity of N-substituted imidazoles and triazoles: the inhibition of isoprenoid biosynthesis. Pesticide Sciences, 15, 188-198.
256. Vanden Bossche, H. & Marichal, P. (1991) Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. American Journal of Obstetrics and Gynecology, 165, 1193-1199.
257. Vanden Bossche, H., Marichal, P., Gorrens, J., Bellens, D., Moereels, H. & Janssen, P.A.J. (1990) Mutation in cytochrome P450-dependent 14α-demethylase results in decreased affinity for azole antifungals. Biochemical Society Transactions, 18, 56-59.
258. Vanden Bossche, H., Marichal, P., Gorrens, J., Bellens, D., Verhoeven, H., Coene, M.-C., Lauwers, W. & Janssen, P.A.J. (1987b) Interaction of azole derivatives with cytochrome P450 isozymes in yeast, fungi, plants and mammalian cells. Pesticide Sciences, 21, 289-306.
259. Vanden Bossche, H., Marichal, P., Gorrens, J., Coene, M.-C., Willemsens, G., Bellens, D., Roels, I., Moereels, H. & Janssen, P.AJ. (1989) Biochemical approaches to selective antifungal activity. Focus on azole antifungals. Mycoses, 32 (Suppl. 1), 35-52.
260. Vanden Bossche, H., Marichal, P., Gorrens, J., Geerts, H. & Janssen, P.A.J. (1988) Mode of action studies. Basis for the search of new antifungal drugs. Annals of the New York Academy of Sciences, 544, 191-207.
261. Vanden Bossche, H., Marichal, P., Le Jeune, L., Coene, M.-C., Gorrens, J. & Cools, W. (1993b) Effects of itraconazole on cytochrome P450-dependent sterol 14α-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy, 37, 2101-2105.
262. Vanden Bossche, H., Marichal, P. & Odds, F.C. (1994a) Molecular mechanisms of drug resistance in fungi. Trends in Microbiology, 2, 393-400.
263. Vanden Bossche, H., Marichal, P., Odds, F.C., Le Jeune, L. & Coene, M.-C.(1992) Charaterization of an azole-resistant Candida glabrata isolate. Antimicrobial Agents and Chemotherapy, 36, 2602-2610.
264. Vanden Bossche, H., Ruysschaert, J.M., Defrise-quertain, F., Willemsens, G., Cornelissen, F., Marichal, P., Cools, W. & Van Cutsem, J. (1982) The interaction of miconazole and ketoconazole with lipids. Biochemical Pharmacology, 31, 2609-2617.
265. Vanden Bossche, H., Warnock, D.W., Dupont, B., Kerridge, D., Sen Gupta, S., Improvisi, L., Marichal, P., Odds, F.C., Provost, F. & Ronin, O. (1994b) Mechanisms and clinical impact of antifungal drug resistance. Journal of Medical and Veterinary Mycology, 32 (Suppl. 1), 189-202.
266. Vanden Bossche, H., Willemsens, G., Cools, W., Cornelissen, F., Lauwers, F. & Van Cutsem, J. (1980) In vitro and in vivo effects of ketoconazole on sterol synthesis. Antimicrobial Agents and Chemotherapy, 17, 922-928.
267. Vanden Bossche, H., Willemsens, G., Cools, W., Lauwers, W.F.J. & Le Jeune, L. (1978) Biochemical effects of miconazole on fungi II: Inhibition of ergosterol biosynthesis in Candida albicans. Chemical Biological Interactions, 21, 59-78.
268. Vanden Bossche, H. Willemsens, G. & Marichal, P. (1987a) Anti-candida drugs - the biochemical basis for their activity. CRC Critical Reviews in Microbiology, 15, 57-72.
269. Venkatakrishnan, K., von Moltke, L.L. & Greenblatt, D.J. (2000) Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clinical Pharmacokinetics, 38, 111-180.
270. Venkateswarlu, K., Denning, D.W., Manning, N.J. & Kelly, S.L. (1995) Resistance to fiuconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. FEMS Microbiology Letters, 131, 337-341.
271. Venkateswarlu, K., Taylor, M., Manning, N.J., Rinaldi, M.G. & Kelly, S.L. (1997) Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy, 41, 748-751.
272. Vermes, A., Guchelaar, H.J. & Dankert, J. (2000) Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. Journal of Antimicrobial Chemotherapy, 46, 171-179.
273. Walsh, T.J., Melcher, G.P., Rinaldi, M.G., Lecciones, J., McGough, D.A., Kelly, P., Lee, J., Callender, D., Rubin, M. & Pizzo, P.A. (1990) Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. Journal of Clinical Microbiology, 28, 1616-1622.
274. Watson, P.F., Rose, M.E., Ellis, S.W., England, H. & Kelly, S.L. (1989) Defective sterol C5-6 desaturation and azole resistance: a new hypothesis for the mode of action of azole antifungals. Biochemical Biophysical Research Communications, 164, 1170-1175.
275. Whelan, W.L. (1987) The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans. CRC Critical Reviews In Microbiology, 15, 45-56.
276. White, T.C. (1997) The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole -resistant lanosterol 14α-demethylase in Candida albicans. Antimicrobial Agents and Chemotherapy, 41, 1488-1494.
277. White, T.C., Marr, K.A. & Bowden, R.A. (1998) Clinical, cellular, an molecular factors that contribute to antifungal drug resistance. Clinical Microbiology Reviews, 11, 382-402.
278. Williams, D.J., Marten, R.M. & Sarkany, I. (1958) Oral treatment of ringworm with griseofulvin. Lancet, 2, 1212.
279. Wilm, K. & Stahl, A.J.C. (1983) Effects of econazole nitrate on yeast cells and mitochondria. Biochemical Pharmacology, 32, 1825-1830.
280. Ziogas, B.N., Sisler, H.D. & Lucas, W.R. (1983) Sterol content and other characteristics of pimaricin-resistant mutants of Aspergillus nidulans. Pesticide Biochemistry and Physiology, 20, 320-329.